CIC
TSHA icon

Cornercap Investment Counsel’s Taysha Gene Therapies TSHA Stock Holding History

Cornercap Investment Counsel’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-55,359
Closed -$44.2K – 663
2023
Q1 		$44.2K Hold
55,359
– – 0.01% 544
2022
Q4 		$125K Buy
55,359
+1,006
+2% +$2.04K 0.02% 529
2022
Q3 		$105K Buy
54,353
+14,597
+37% +$53K 0.02% 526
2022
Q2 		$148K Buy
+39,756
New +$158K 0.03% 506

Other funds holding TSHA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cornercap Investment Counsel's TSHA Position: Q2 2023 in Review

Cornercap Investment Counsel sold out of Taysha Gene Therapies (TSHA) in Q2 2023, closing a stake of 55,359 shares — an estimated $44.2K sold.

Cornercap Investment Counsel first reported a position in TSHA in Q2 2022 and held it in 4 quarters. The position peaked at $148K in Q2 2022. 39 funds tracked by Wall St. Rank hold TSHA as of Q2 2023.

  • Cornercap Investment Counsel reported no remaining Taysha Gene Therapies position as of Q2 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 55,359 Taysha Gene Therapies shares in Q2 2023, an estimated $44.2K.
  • Cornercap Investment Counsel first reported a position in Taysha Gene Therapies in Q2 2022 and held it in 4 quarters.
  • Cornercap Investment Counsel's Taysha Gene Therapies position peaked at $148K in Q2 2022.
  • 39 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2023.

Based on Cornercap Investment Counsel's 13F filing for Q2 2023, filed 11 Aug 2023.